Clinical significance of angiogenic factors in breast cancer.

Abstract:

:Growth, progression, and metastasis of breast cancer, as well as of most of the other tumors, are angiogenesis-dependent processes. Several pro-angiogenic growth factors and endogenous inhibitors of angiogenesis have been identified and sequenced, and experimental studies suggest that angiogenic activity of a tumor may result from downregulation of inhibitors of angiogenesis or up-regulation of endothelial growth factors. The mechanisms leading to the alteration of the balance between positive and negative modulators of angiogenesis are only partially known. We are at the beginning of research to identify the more active angiogenic factors in human breast cancer, and little information is presently available on their clinical significance. Preliminary results suggest that among the known angiogenic peptides, both vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor / thymidine phosphorylase (PD-ECGF/TP) have promising prognostic and, perhaps, predictive value. No data are available on the clinical value of co-determination of positive and negative regulators of angiogenesis to look at the angiogenic balance of each single tumor. Only a few studies have assessed the role of endogenous inhibitors of angiogenesis in human breast cancer, with results available only on thrombospondin-1 and -2 (TSP-1, -2). Finally, the determination of some integrins such as alpha6 and alphavbeta3 and of some other endothelial-adhesion molecules seems to be of potential prognostic value. Recognizing which are the more biologically active positive and negative angiogenic factors is the key for the identification not only of new prognostic markers but also of targets for antiangiogenic therapy in human breast cancer.

authors

Locopo N,Fanelli M,Gasparini G

doi

10.1023/a:1006175504673

subject

Has Abstract

pub_date

1998-01-01 00:00:00

pages

159-73

issue

1-3

eissn

0167-6806

issn

1573-7217

journal_volume

52

pub_type

杂志文章,评审
  • Prognostic factors for patients with breast cancers 1cm and smaller.

    abstract::The widespread use of mammography has resulted in the detection of an increasing number of small invasive breast cancers, i.e. those that are 1cm and smaller. Patients with these small cancers generally have a low incidence of axillary lymph node metastases, and this has led some to question the routine use of axillar...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1006130911110

    authors: Chen YY,Schnitt SJ

    更新日期:1998-01-01 00:00:00

  • Predictors of time to death after distant recurrence in breast cancer patients.

    abstract:BACKGROUND:After experiencing a distant recurrence, breast cancer patients have a poor prognosis; fewer than 5% survive for ten or more years. However, the time to death is highly variable, ranging from a few months to many years. The purpose of this study is to identify, in a large hospital-based series of patients wi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-5002-9

    authors: Sopik V,Sun P,Narod SA

    更新日期:2019-01-01 00:00:00

  • The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.

    abstract::The aromatase inhibitors (AIs) are used to treat estrogen receptor-positive (ER+) breast tumors in post-menopausal women, and function by blocking the conversion of adrenal androgens to estrogens by the enzyme CYP19 aromatase. Breast cancer patients receiving AI therapy have circulating estrogen levels below the level...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0080-8

    authors: Sikora MJ,Cordero KE,Larios JM,Johnson MD,Lippman ME,Rae JM

    更新日期:2009-05-01 00:00:00

  • The impact of sharing results of a randomized breast cancer clinical trial with study participants.

    abstract:BACKGROUND:There has been growing interest in providing clinical trial participants with study results yet only limited information exists regarding the process and impact of sharing results. We sought to evaluate patient perceptions of how results had been shared from a large randomized cooperative group trial, and th...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-008-0057-7

    authors: Partridge AH,Wolff AC,Marcom PK,Kaufman PA,Zhang L,Gelman R,Moore C,Lake D,Fleming GF,Rugo HS,Atkins J,Sampson E,Collyar D,Winer EP

    更新日期:2009-05-01 00:00:00

  • Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.

    abstract::The high potency and selectivity of new aromatase inhibitors has translated to greater efficacy and improved tolerability in comparison with established second-line hormonal agents for advanced breast cancer in phase III clinical trials. Two pharmacological studies are reported which assess the use of one of these inh...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1006289811540

    authors: Dowsett M,Doody D,Miall S,Howes A,English J,Coombes RC

    更新日期:1999-07-01 00:00:00

  • Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.

    abstract::Tamoxifen is metabolized into endoxifen, a potent antagonist of the estrogen receptor, in part through cytochrome p450 (CYP) 2D6. Genotypic variation in CYP2D6 affects endoxifen levels, and some have argued that patients who do not efficiently metabolize tamoxifen might wish to consider alternative hormonal treatments...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-013-2700-1

    authors: Ruddy KJ,Desantis SD,Gelman RS,Wu AH,Punglia RS,Mayer EL,Tolaney SM,Winer EP,Partridge AH,Burstein HJ

    更新日期:2013-10-01 00:00:00

  • The association of SULT1A1 codon 213 polymorphism and breast cancer susceptibility: meta-analysis from 16 studies involving 23,445 subjects.

    abstract::Epidemiological studies on the association between SULT1A1 codon 213 polymorphism and breast cancer risk are inconclusive. In order to derive a more precise estimation of the association, a meta-analysis was conducted in this article. Sixteen studies including 9,881 cases and 13,564 controls were collected for SULT1A1...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-010-0953-5

    authors: Sun Y,Zang Z,Xu X,Zhang Z,Zhong L,Zan W,Zhao Y,Sun L

    更新日期:2011-01-01 00:00:00

  • Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.

    abstract::Our aim was to analyze the incidence of mutations in BRCA1 and BRCA2 genes in 54 families with breast/ovarian cancer. Families were selected from three Institutions following the standard criteria for hereditary breast/ovarian cancer. PCR amplification of all exons was performed, followed by SSCP, heteroduplex, PTT an...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-9047-1

    authors: Gallardo M,Silva A,Rubio L,Alvarez C,Torrealba C,Salinas M,Tapia T,Faundez P,Palma L,Riccio ME,Paredes H,Rodriguez M,Cruz A,Rousseau C,King MC,Camus M,Alvarez M,Carvallo P

    更新日期:2006-01-01 00:00:00

  • Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample.

    abstract:PURPOSE:To investigate the discordance between original and central laboratories in estrogen receptor (ER) status, in tumors originally deemed to be ER-negative, and in HER2 status in a diverse population-based sample. METHODS:In a follow-up study of 1785 women with Stage I-III breast cancer diagnosed between 2005 and...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-4061-z

    authors: Griggs JJ,Hamilton AS,Schwartz KL,Zhao W,Abrahamse PH,Thomas DG,Jorns JM,Jewell R,Saber ME,Haque R,Katz SJ

    更新日期:2017-01-01 00:00:00

  • Differential retention of rhodamine 123 by breast carcinoma and normal human mammary tissue.

    abstract::We have qualitatively evaluated the retention of the fluorescent dye rhodamine 123 by malignant or non-malignant breast epithelial cells in passively-infused fresh surgical specimens. Our findings demonstrate a microscopically-visible increase in the ability of primary and metastatic tumor cells to retain the dye, as ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01975444

    authors: Dairkee SH,Hackett AJ

    更新日期:1991-03-01 00:00:00

  • Digital compared to screen-film mammography: breast cancer prognostic features in an organized screening program.

    abstract::Our previous study found cancer detection rates were equivalent for direct radiography compared to screen-film mammography, while rates for computed radiography were significantly lower. This study compares prognostic features of invasive breast cancers by type of mammography. Approved by the University of Toronto Res...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3088-2

    authors: Prummel MV,Done SJ,Muradali D,Majpruz V,Brown P,Jiang H,Shumak RS,Yaffe MJ,Holloway CM,Chiarelli AM

    更新日期:2014-09-01 00:00:00

  • Adjuvant systemic therapy: state of the art, 1989.

    abstract::After more than 100 reported randomized trials of systemic adjuvant therapy in breast cancer, it is clear that this therapy will prolong the time to recurrence and the survival time significantly, at least in some patient subsets. But there is less than complete agreement as to which subsets, which therapies, how much...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验,评审

    doi:10.1007/BF01805971

    authors: Henderson IC

    更新日期:1989-10-01 00:00:00

  • Fruits, vegetables, and micronutrient intake in relation to breast cancer survival.

    abstract:OBJECTIVE:To determine whether fruit, vegetable, and micronutrient intake 1 year prior to breast cancer diagnosis is associated with a reduction in the subsequent risk of all-cause or breast cancer-specific mortality. METHODS:Follow-up data from 1,235 invasive breast cancer cases age 25-98 years from the Long Island B...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-9150-3

    authors: Fink BN,Gaudet MM,Britton JA,Abrahamson PE,Teitelbaum SL,Jacobson J,Bell P,Thomas JA,Kabat GC,Neugut AI,Gammon MD

    更新日期:2006-07-01 00:00:00

  • The polymorphic CAG repeat of the androgen receptor gene: a potential role in breast cancer in women over 40.

    abstract::Previous investigations into the relationship of CAG-repeat lengths in the androgen receptor (AR) gene to female breast cancer (BC) have yielded somewhat confusing results. Decreased AR transactivational activity lowers androgen:estrogen balance, and may thereby effect functional hyperestrogenicity. This may promote t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1012942910375

    authors: Elhaji YA,Gottlieb B,Lumbroso R,Beitel LK,Foulkes WD,Pinsky L,Trifiro MA

    更新日期:2001-11-01 00:00:00

  • Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer.

    abstract::While overall survival (OS) has historically been the primary endpoint for clinical trials in oncology, progression-free survival (PFS) has gained acceptance as a valuable surrogate endpoint. However, there are no known published reports about the value of PFS from the patient's perspective. We developed a questionnai...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2734-4

    authors: Hurvitz SA,Lalla D,Crosby RD,Mathias SD

    更新日期:2013-12-01 00:00:00

  • MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism.

    abstract::NF-E2-related factor 2 (Nrf2) is an important transcription factor involved in antioxidant response. Nrf2 binds antioxidant response elements (ARE) within promoters of genes encoding detoxification enzymes (e.g., NAD (P) H-quinone oxidoreductase 1 (NQO1)) leading to their transcriptional activation. Nrf2 function is r...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1604-1

    authors: Yang M,Yao Y,Eades G,Zhang Y,Zhou Q

    更新日期:2011-10-01 00:00:00

  • A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity.

    abstract::A model for a more precise prognosis of the risk of relapse is needed to avoid overtreatment of lymph node-negative breast cancer patients. A large derivation data set (n = 684) was generated by pooling three independent breast cancer expression microarray data sets. Two major prognostic factors, proliferation and imm...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1626-8

    authors: Oh E,Choi YL,Park T,Lee S,Nam SJ,Shin YK

    更新日期:2012-04-01 00:00:00

  • Breast cancer and timing of surgery during menstrual cycle: a 5-year analysis of 248 premenopausal women.

    abstract::In the present report, we retrospectively analyzed the impact of the timing of surgery during menstrual cycle on disease-free and overall survival of 248 premenopausal patients with stage I/II breast cancer who underwent surgery followed by anthracycline-containing adjuvant chemotherapy. With a median follow-up of 5 y...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1023/a:1006276120841

    authors: Milella M,Nisticò C,Ferraresi V,Vaccaro A,Fabi A,D'Ottavio AM,Botti C,Giannarelli D,Lopez M,Cortesi E,Foggi CM,Antimi M,Terzoli E,Cognetti F,Papaldo P

    更新日期:1999-06-01 00:00:00

  • The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115).

    abstract:PURPOSE:In Brazil, the available cancer registries are deficient in number and quality and, hence, little information is known regarding sociodemographic, clinicopathological characteristics, treatment patterns, and outcomes of breast cancer (BC) patients. We performed the AMAZONA III/ GBECAM 0115 study and in this ana...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05831-y

    authors: Rosa DD,Bines J,Werutsky G,Barrios CH,Cronemberger E,Queiroz GS,de Lima VCC,Freitas-Júnior R,Couto JD,Emerenciano K,Resende H,Crocamo S,Reinert T,Van Eyil B,Nerón Y,Dybal V,Lazaretti N,de Cassia Costamilan R,de Andrad

    更新日期:2020-10-01 00:00:00

  • Pre-operative progesterone benefits operable breast cancer patients by modulating surgical stress.

    abstract:PURPOSE:We have reported a survival benefit of single injection of hydroxyprogesterone prior to surgery for primary tumour in patients with node-positive operable breast cancer. Hydroxyprogesterone was meant to recapitulate the luteal phase of menstrual cycle in these women. We wanted to understand the molecular basis ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4749-3

    authors: Chatterjee S,Chaubal R,Maitra A,Gardi N,Dutt A,Gupta S,Badwe RA,Majumder PP,Pandey P

    更新日期:2018-07-01 00:00:00

  • Predictors of distant metastasis at presentation in breast cancer: a study also evaluating associations among common biological indicators.

    abstract:BACKGROUND:To investigate the correlation among some of the commonly used clinical, pathological factors and newer biological indicators, and to identify the independent predictors of distant metastasis at presentation in patients with breast cancer. METHODS:The pathological specimens from 73 patients with breast canc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1012269804578

    authors: Bozcuk H,Uslu G,Peştereli E,Samur M,Ozdoğan M,Karaveli S,Sargin F,Savaş B

    更新日期:2001-08-01 00:00:00

  • The nude mouse as an in vivo model for human breast cancer invasion and metastasis.

    abstract::Human breast cancer xenografts only rarely invade and metastasize in nude mice, and have therefore only had limited use as a model for studying mechanisms involved in breast cancer spreading. However, recent reports describe differences not only between various cell lines but also between strains of immune-deficient m...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01833265

    authors: Brünner N,Boysen B,Rømer J,Spang-Thomsen M

    更新日期:1993-01-01 00:00:00

  • Outcomes of a weight loss intervention among rural breast cancer survivors.

    abstract::Obese breast cancer survivors have increased risk of recurrence and death compared to their normal weight counterparts. Rural women have significantly higher obesity rates, thus weight control intervention may be a key strategy for prevention of breast cancer recurrence in this population. This one-arm treatment study...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s10549-011-1922-3

    authors: Befort CA,Klemp JR,Austin HL,Perri MG,Schmitz KH,Sullivan DK,Fabian CJ

    更新日期:2012-04-01 00:00:00

  • Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant.

    abstract::This prospective study assessed the endometrial effects of fulvestrant, a pure estrogen-receptor antagonist, in postmenopausal women with breast cancer. This single-center study enrolled postmenopausal patients who had an intact uterus at baseline with progressive metastatic breast cancer on tamoxifen followed by an o...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-008-0248-2

    authors: Morales L,Neven P,Timmerman D,Wildiers H,Konstantinovic ML,Christiaens MR,Tan PN,Paridaens R

    更新日期:2009-09-01 00:00:00

  • Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients.

    abstract:PURPOSE:In left-sided breast cancer radiotherapy, tangential intensity modulated radiotherapy combined with breath-hold enables a dose reduction to the heart and left anterior descending (LAD) coronary artery. Aim of this study was to investigate the added value of intensity modulated proton therapy (IMPT) with regard ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3149-6

    authors: Mast ME,Vredeveld EJ,Credoe HM,van Egmond J,Heijenbrok MW,Hug EB,Kalk P,van Kempen-Harteveld LM,Korevaar EW,van der Laan HP,Langendijk JA,Rozema HJ,Petoukhova AL,Schippers JM,Struikmans H,Maduro JH

    更新日期:2014-11-01 00:00:00

  • Transforming growth factor-beta in breast cancer: a working hypothesis.

    abstract::Transforming Growth Factor-beta (TGF beta) is the most potent known inhibitor of the progression of normal mammary epithelial cells through the cell cycle. During the early stages of breast cancer development, the transformed epithelial cells appear to still be sensitive to TGF beta-mediated growth arrest, and TGF bet...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1005865812918

    authors: Reiss M,Barcellos-Hoff MH

    更新日期:1997-08-01 00:00:00

  • Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families.

    abstract::Although a significant proportion of familial aggregation of breast cancer remains unexplained, many of the currently known breast cancer susceptibility genes, including BRCA1, BRCA2 and TP53, play a role in maintaining genome integrity by engaging in DNA repair. RAD51L1 is one of the five RAD51 paralogs involved in h...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1539-6

    authors: Johnson J,Healey S,Khanna KK,kConFab.,Chenevix-Trench G

    更新日期:2011-08-01 00:00:00

  • DNA-repair genetic polymorphisms and risk of breast cancer in Cyprus.

    abstract::The DNA repair pathway is known to play a role in the etiology of breast cancer. A number of studies have demonstrated that common germline variants in genes involved in the DNA repair pathway influence breast cancer risk. To assess whether alterations in DNA repair genes contribute to breast cancer, we genotyped 12 s...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0084-4

    authors: Loizidou MA,Michael T,Neuhausen SL,Newbold RF,Marcou Y,Kakouri E,Daniel M,Papadopoulos P,Malas S,Hadjisavvas A,Kyriacou K

    更新日期:2009-06-01 00:00:00

  • Is microductectomy still necessary to diagnose breast cancer: a 10-year study on the effectiveness of duct excision and galactography.

    abstract:PURPOSE:Patients with spontaneous nipple discharge (SND) who have neither clinically palpable masses nor evidence of disease on imaging with mammogram and/or ultrasound are traditionally investigated with galactogram and duct excision. As breast imaging improves, it has raised the question whether galactography and mic...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-05109-4

    authors: Lustig DB,Warburton R,Dingee CK,Kuusk U,Pao JS,McKevitt EC

    更新日期:2019-04-01 00:00:00

  • 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.

    abstract:BACKGROUND:The Van Nuys Prognostic Index (VNPI) is a simple score for predicting the risk of local recurrence (LR) in patients with Ductal Carcinoma In Situ (DCIS) conservatively treated. This score combines three independent predictors of Local Recurrence. The VNPI has recently been updated with the addition of age as...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-007-9668-7

    authors: Di Saverio S,Catena F,Santini D,Ansaloni L,Fogacci T,Mignani S,Leone A,Gazzotti F,Gagliardi S,De Cataldis A,Taffurelli M

    更新日期:2008-06-01 00:00:00